How to Buy Arcutis Biotherapeutics Stock
Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc. , a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Arcutis Biotherapeutics stock last closed at $23.95, down 2.6% from the previous day, and has increased 54.62% in one year. It has overperformed other stocks in the Biotechnology industry by 1.07 percentage points. Arcutis Biotherapeutics stock is currently +101.94% from its 52-week low of $11.86, and -24.61% from its 52-week high of $31.77.
As of Mar 11, 2026, there are 124.03M ARQT shares outstanding. The market cap of ARQT is $2.97B. In the past 24 hours, 605,000 ARQT shares were traded.
How to Buy Arcutis Biotherapeutics Stock
Wondering how to invest in Arcutis Biotherapeutics stock? Here's how.
- Choose where to buy Arcutis Biotherapeutics stock: You need to pick an online brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you determine where to buy Arcutis Biotherapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit money your investment account: Pick your payment method and add your info.
- Analyze Arcutis Biotherapeutics stock: The Arcutis Biotherapeutics ticker symbol is ARQT. Is Arcutis Biotherapeutics stock a good investment? Should you buy shares of ARQT? How do ARQT's underlying business fundamentals look? Do top analysts think Arcutis Biotherapeutics is a good buy? Why has ARQT's stock price moved recently? (Hint: Our stock research website can help you figure out if ARQT is a good stock to buy).
- Place your ARQT trade: Decide if you will purchase ARQT shares at the current market price or use a limit order to buy ARQT stock at a specific price.
- Watch your investment in ARQT: Create a watchlist to keep track of your investment in Arcutis Biotherapeutics stock.
Step 1: Choose where to buy Arcutis Biotherapeutics stock
You need an online brokerage account to access the NASDAQ market and buy ARQT shares.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. Here's why:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global markets: From Technology to Energy, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've picked the right brokerage, you'll need to fill out some personal information so you are able to buy ARQT stock today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to open a new trading account.
- Submit your data by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you've finished signing up on the best stock market app for beginners, your next step is to transfer the money for your investment:
Watch the walkthrough below to see the process of transferring money into your new investment account.
Step 4: Analyze Arcutis Biotherapeutics stock
Once you have figured out the best place to buy Arcutis Biotherapeutics stock, it's critical to analyze their stock before you buy, so you actually wrap your head around the risk as well as the opportunity.
Arcutis Biotherapeutics quick stats
ARQT Due Diligence Score
WallStreetZen was created to help average investors perform better fundamental analysis quickly.
You can see all of the due diligence checks on ARQT's stock page.
How is ARQT stock valued?
You can use many financial metrics, analyses, models, and charts to gauge ARQT's fair value.
Using relative valuations measures:
- ARQT may be overvalued based on its P/B ratio of 15.68x, relative to Biotechnology industry P/B ratio of 4.87x
You can access additional valuation research on ARQT's stock here.
A quick look at ARQT Financials
Positive Health Checks:
- There are more short-term assets than short-term liabilities on the ARQT balance sheet.
- ARQT has cash burn of 6311000. It has sufficient cash and short-term investments to cover this for at least one year.
- ARQT profit margin has gone up from -71.3% to -4.3% in the past year.
- ARQT has $221.29M in cash and short term investments. This is sufficient to cover its annual cash burn of $6.31M.
- There are more short-term assets than long-term liabilities on the ARQT balance sheet.
Negative Health Checks:
- ARQT has a relatively high debt to equity ratio of 1.29.
- Total ARQT debt is higher than 5 years ago, relative to shareholder equity.
Do analysts think it's a good time to buy ARQT stock
Out of 6 Wall Street analysts who give forecasts on ARQT, the consensus analyst rating on Arcutis Biotherapeutics is a Buy
It's important to note that analyst forecasts are not recommendations, nor are they investment advice.
Most Recent ARQT Analyst Recommendations
Richard Law, a top 17% analyst from Goldman Sachs maintains ARQT with a hold rating and raises their ARQT price target from $19.00 to $29.00, on Oct 30, 2025.
You can dig deeper into what analysts are projecting on the Arcutis Biotherapeutics stock forecast page.
ARQT Momentum
How are ARQT Revenues/Earnings doing?
Last year, ARQT revenue was $376.07M. Over the last three year, ARQT's revenue has gone up by 465.74% per year. This was faster than the Biotechnology industry average of 29.32%.
Learn more about ARQT's earnings and revenue performance here.
Are ARQT insiders buying or selling the stock?
Over the last 12 months, executives and large shareholders at ARQT have sold more shares than they have bought.
Patrick Burnett, Reporting Persons title EVP Chief Medical Officer of ARQT, was the latest ARQT insider to sell. They sold $153,626.96 worth of ARQT stock on Mar 2, 2026.
Dig into more about who owns ARQT stock here.
Does ARQT stock generate passive income?
No, Arcutis Biotherapeutics doesn't provide an income stream by paying out dividends.
ARQT Social Trading Data
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your ARQT trade
There are two primary options:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are usually the best for newer investors. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a given dollar amount, place a limit order.
Hit the Open button and eToro will place your order.
If you want more assistance buying stocks on eToro, watch the helpful video below:
Step 6: Watch your investment in ARQT
Now that you own some ARQT stock, you'll want to keep up with your investment.
Create a watchlist to get notified of important updates regarding your ARQT stock.
ARQT Feed
How to Buy Stock in Arcutis Biotherapeutics
To summarize, here are the 6 steps to buy Arcutis Biotherapeutics stock:
- Choose where to buy Arcutis Biotherapeutics stock
- Open your brokerage account
- Deposit money your investment account
- Analyze Arcutis Biotherapeutics stock
- Place your ARQT trade
- Watch your investment in ARQT
If you need a place to buy stocks, eToro is our favorite option.
Get Started with eToro TodayIf you want to monitor your investment in Arcutis Biotherapeutics, create a watchlist on WallStreetZen today.
Related "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.